Dr. Reddy's (RDY) partners with Shanghai Henlius Biotech to develop and market biosimilar versions of J&J's (JNJ) multiple ...

Dr Reddy's Laboratories has signed a licence agreement with Shanghai Henlius Biotech to develop and commercialise HLX15, a ...

HLX15 is being developed as a biosimilar of Darzalex® & Darzalex Faspro®*, which are indicated for the treatment of multiple myeloma. The agreement combines Dr. Reddy’s global commercial ...

Genmab (NASDAQ:GMAB), a biotechnology company with a market capitalization of $16.91 billion specializing in cancer treatments, particularly multiple myeloma, has been making waves in the ...

Dr Reddy’s inks pact with Henlius to commercialize HLX1, a biosimilar candidate in US & Europe: Our Bureau, Bengaluru Thursday, February 6, 2025, 17:20 Hrs [IST] Dr Reddy’s La ...

What Does the Darzalex Faspro Market Look Like? The darzalex faspro market witnessed significant growth in recent years with recorded XX in historic compound annual growth rate HCAGR. Within a ...

sold under the tradename DARZALEX FASPRO ® in the U.S.), as reported by J&J were USD 11,670 million in 2024. Net trade sales were USD 6,588 million in the U.S. and USD 5,082 million in the rest ...

sold under the tradename DARZALEX FASPRO ® in the U.S.), as reported by J&J were USD 11,670 million in 2024. Net trade sales were USD 6,588 million in the U.S. and USD 5,082 million in the rest of the ...

Darzalex & Darzalex Faspro are indicated to treat multiple myeloma. The partnership leverages Dr. Reddy's worldwide commercial network along with Henlius' expertise in biosimilar development.